What is NewcelX Ltd.?
, a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 15.08M, and a P/E ratio of 5.0x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.